Adaptimmune
Clinical trials sponsored by Adaptimmune, explained in plain language.
A clinical-stage biopharmaceutical company developing T-cell therapies for cancer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
Engineered immune cells take on liver cancer in early trial
Disease control CompletedThis early-phase trial tested a new approach for advanced liver cancer that has not responded to standard treatments. Researchers took participants' own immune cells, modified them in a lab to target a protein called AFP found on cancer cells, and infused them back after a short …
Phase: PHASE1 • Sponsor: Adaptimmune • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Engineered T-Cells take aim at bladder, skin, and head and neck cancers
Disease control CompletedThis early-phase study tested whether genetically modified T-cells (MAGE-A10ᶜ⁷⁹⁶T) are safe for people with advanced urothelial cancer, melanoma, or head and neck cancer. Ten participants received their own engineered immune cells after chemotherapy. The main goal was to check fo…
Phase: PHASE1 • Sponsor: Adaptimmune • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Engineered t cells take on lung cancer in early trial
Disease control CompletedThis early-stage trial tested a new treatment for people with advanced non-small cell lung cancer that had grown after standard therapy. Researchers took patients' own immune cells, genetically modified them to recognize and attack cancer cells, and infused them back after chemot…
Phase: PHASE1 • Sponsor: Adaptimmune • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC